Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $0.19 EPS

Rallybio (NASDAQ:RLYB) issued its earnings results on Thursday. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.19, Zacks reports. Rallybio had a negative net margin of 911.07% and a negative return on equity of 47.17%.

Rallybio Trading Down 0.2%

Shares of Rallybio stock traded down $0.03 during trading on Friday, reaching $16.16. The company’s stock had a trading volume of 12,304 shares, compared to its average volume of 42,162. The firm has a market cap of $85.65 million, a PE ratio of -3.72 and a beta of -0.90. Rallybio has a fifty-two week low of $3.20 and a fifty-two week high of $17.57. The company has a 50-day moving average price of $16.05 and a two-hundred day moving average price of $11.40.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc acquired 10,200 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was bought at an average cost of $13.98 per share, with a total value of $142,596.00. Following the transaction, the insider owned 926,352 shares of the company’s stock, valued at $12,950,400.96. The trade was a 1.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders purchased 146,568 shares of company stock worth $2,050,669. 10.30% of the stock is owned by corporate insiders.

Institutional Trading of Rallybio

A number of institutional investors have recently modified their holdings of RLYB. XTX Topco Ltd boosted its stake in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares in the last quarter. Susquehanna International Group LLP grew its stake in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the period. Geode Capital Management LLC grew its stake in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares in the last quarter. Citadel Advisors LLC grew its holdings in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares during the last quarter. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.